Abstract:Adoptive immunotherapy based on chimeric antigen receptor (CAR)-engineered T cells has exhibited impressive clinical efficacy in treating B-cell malignancies. However, the potency of CAR-T cells carriethe potential for significant on-target/off-tumor toxicities when target antigens are shared with healthy cells, necessitating the development of complementary safety measures. In this context, there is a need to selectively eliminate therapeutically administered CAR-T cells, especially to revert long-term CAR-T cell-related side effects. To address this, we have developed an effective cellular-based safety mechanism to specifically target and eliminate the transferred CAR-T cells. As proof-of-principle, we have designed a secondary CAR ( anti -CAR CAR) capable of recognizing a short peptide sequence (Strep-tag II) incorporated into the hinge domain of an anti -CD19 CAR. In in vitro experiments, these anti -CAR CAR-T cells have demonstrated antigen-specific cytokine release and cytotoxicity when co-cultured with anti -CD19 CAR-T cells. Moreover, in both immunocompromised and immunocompetent mice, we observed the successful depletion of anti -CD19 CAR-T cells when administered concurrently with anti -CAR CAR-T cells. We have also demonstrated the efficacy of this safeguard mechanism in a clinically relevant animal model of B-cell aplasia induced by CD19 CAR treatment, where this side effect was reversed upon anti -CAR CAR-T cells infusion. Notably, efficient B-cell recovery occurred even in the absence of any pre-conditioning regimens prior anti -CAR CAR-T cells transfer, thus enhancing its practical applicability. In summary, we developed a robust cellular safeguard system for selective in vivo elimination of engineered T cells, offering a promising solution to address CAR-T cell-related on-target/off-tumor toxicities.

A Pathologist's Guide to Non-clinical Safety Assessment of Adoptive Cell Therapy Products

Finding Your CAR: The Road Ahead for Engineered T Cells

Efficacy and Safety of Adoptive Immunotherapy Using Anti-Cd19 Chimeric Antigen Receptor Transduced T-cells: a Systematic Review of Phase I Clinical Trials.

CAR T cell Toxicities: Bedside to Bench – How Novel Toxicities Inform Laboratory Investigations

The toxicity of cell therapy: Mechanism, manifestations, and challenges

Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects

Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective

A chimeric antigen receptor-based cellular safeguard mechanism for selective in vivo depletion of engineered T cells

Toxicity and management in CAR T-cell therapy

Adoptive Immunotherapy beyond CAR T-Cells

Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer

Current Clinical Application of the CAR-T Cell Therapy

Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity

Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease

Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy

Current understanding and management of CAR T cell-associated toxicities

Clinical Application and Risk Assessment of CAR-T Cell Technology in Cancer Immunotherapy

CAR-T Cell Therapy: the Efficacy and Toxicity Balance

Engineering strategies to mitigate toxicities associated with CAR‐T cell therapy

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies